Our lymphoma research
Lymphoma is a type of cancer that affects cells in the lymphatic system - the network of lymph glands and vessels that helps to protect us from infection.
Four out of every five cases are non-Hodgkin lymphomas, and there are around 10,500 new cases every year in the UK. And around people are diagnosed with Hodgkin's lymphoma every year.
Thanks to improved treatments, survival from lymphoma has significantly increased over the past thirty years. For example, more than 6 out of ten younger patients with non-Hodgkin lymphoma will survive for five years or more.
There is information for people affected by Hodgkin's and non-Hodgkin lymphoma on our CancerHelp UK site.
Below are some of the highlights of our lymphoma research.
Cell death (apoptosis)
Prof Peter Johnson
Cancer Research UK Medical Oncology Unit
University of Southampton, Southampton
Developing new cancer treatments
Professor Peter Johnson is the Cancer Research UK Chair of Medical Oncology and directs the Southampton Clinical Centre. He is also Cancer Research UK's Chief Clinician. In this role, he is helping to shape the future of our clinical research across the UK. Professor Johnson is a leading expert in lymphoma - a cancer that affects the body's white blood cells. He's also working on new treatments that use the power of the body's own immune system to attack tumours.
Chemotherapy
Dr Simon Rule
Derriford Hospital
Plymouth Hospitals NHS Trust, Plymouth
Investigating new treatments for lymphoma
Dr Simon Rule is researching new treatments for lymphoma, a cancer of the white blood cells. His team are carrying out a clinical trial looking at treatments for a rare but aggressive form of the disease called mantle cell lymphoma.
Clinical trials
Dr Simon Rule
Derriford Hospital
Plymouth Hospitals NHS Trust, Plymouth
Investigating new treatments for lymphoma
Dr Simon Rule is researching new treatments for lymphoma, a cancer of the white blood cells. His team are carrying out a clinical trial looking at treatments for a rare but aggressive form of the disease called mantle cell lymphoma.
Epstein Barr virus (EBV)
Prof Alan Rickinson
Cancer Research UK Institute for Cancer Studies
The University of Birmingham, Birmingham
Understanding viruses that cause cancer
Professor Alan Rickinson is a world expert on the Epstein-Barr virus (EBV). This virus is linked to certain types of cancer including Hodgkin's lymphoma and Burkitt's lymphoma - cancers that arise from cells of the immune system.
Prof Lawrence Young
Cancer Research UK Institute for Cancer Studies
The University of Birmingham, Birmingham
Understanding viruses that cause cancer
Professor Lawrence Young is Head of College of Medical and Dental Sciences at the University of Birmingham. Together with his team, he is investigating how Epstein-Barr virus (EBV) infection is linked to certain types of cancer including Hodgkin's lymphoma and nasopharyngeal cancer.
Immunotherapy
Prof Peter Johnson
Cancer Research UK Medical Oncology Unit
University of Southampton, Southampton
Developing new cancer treatments
Professor Peter Johnson is the Cancer Research UK Chair of Medical Oncology and directs the Southampton Clinical Centre. He is also Cancer Research UK's Chief Clinician. In this role, he is helping to shape the future of our clinical research across the UK. Professor Johnson is a leading expert in lymphoma - a cancer that affects the body's white blood cells. He's also working on new treatments that use the power of the body's own immune system to attack tumours.
Prof Christian Ottensmeier
Cancer Sciences Division, School of Medicine
University of Southampton, Southampton
Cancer vaccines - harnessing the immune system to fight cancer
Professor Christian Ottensmeier and his team based at Southampton General Hospital are at the forefront of research into cancer vaccines. This novel approach to cancer treatment aims to stimulate the body's own immune system to recognise and kill the cancer cells. The technique is being tested as a treatment for cancers such as lymphoma and myeloma.
Increase text
Decrease text
Print this page
